Online inquiry

IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8667MR)

This product GTTS-WQ8667MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM), AL amyloidosis research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ8667MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12242MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ8688MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ782MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Ab-2
GTTS-WQ5776MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ8212MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA hLIV22
GTTS-WQ1257MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABT-165
GTTS-WQ4548MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-936564
GTTS-WQ9737MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JR-141
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW